GGrantIndex
Sort

10,829 grants matching car t

I4C 2.0: Immunotherapy for Cure

$4,653,643
Dan H. Barouch · Beth Israel Deaconess Medical Center · UM1 · FY2025 · AI

PRE-IND STUDIES OF FIRST-GENERATION DUAL-TARGETED, FINE-TUNED, IMMUNE-RESTORING (DFIR) CAR-T CELL THERAPY TO ACHIEVE CURES OF CLEAR CELL RENAL CELL CARCINOMA (CCRCC)

$4,650,116
Dana-Farber Cancer Institute, Inc. · · FY2021 · Defense Health Agency

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

$4,589,036
Luis J. Montaner · Wistar Institute · UM1 · FY2016 · AI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

$4,589,036
Luis J. Montaner · Wistar Institute · UM1 · FY2019 · AI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

$4,589,036
Luis J. Montaner · Wistar Institute · UM1 · FY2018 · AI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

$4,589,035
Luis J. Montaner · Wistar Institute · UM1 · FY2017 · AI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

$4,589,035
Luis J. Montaner · Wistar Institute · UM1 · FY2020 · AI

Cell and Gene Therapy for HIV Cure

$4,564,019
Keith R Jerome · Fred Hutchinson Cancer Research Center · UM1 · FY2020 · AI

FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL USING TRISPECIFIC (CD19/CD20/CD22) CAR T CELLS FOR THE TREATMENT OF RELAPSED/REFRACTORY B CELL LYMPHOMA

$4,523,000
University Of Maryland, Baltimore · · FY2025 · Defense Health Agency

Columbia/Cornell/Harlem Hospital Precision Medicine Initiative HPO

$4,461,312
David B. Goldstein · Columbia University Health Sciences · UG3 · FY2016 · OD

Adaptive Platform for Personalized Engagement

$4,454,562
Praduman Jain · Vignet, Inc. · U24 · FY2020 · OD

I4C 2.0: Immunotherapy for Cure

$4,423,055
Dan H. Barouch · Beth Israel Deaconess Medical Center · UM1 · FY2024 · AI

Stanford Cancer Institute

$4,416,653
Steven E Artandi · Stanford University · P30 · FY2025 · CA

Adult Leukemia Research Center

$4,395,431
Geoffrey Roger Hill · Fred Hutchinson Cancer Center · P01 · FY2025 · CA

Adult Leukemia Research Center

$4,359,202
Geoffrey Roger Hill · Fred Hutchinson Cancer Center · P01 · FY2024 · CA

Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation

$4,303,502
Ali Naji · University Of Pennsylvania · U01 · FY2025 · AI

CD79B-TARGETING CAR T-CELL THERAPY FOR B-CELL LYMPHOMAS

$4,275,962
The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2024 · Defense Health Agency

Stanford Cancer Institute

$4,223,653
Steven E Artandi · Stanford University · P30 · FY2023 · CA

Stanford Cancer Institute

$4,223,653
Steven E Artandi · Stanford University · P30 · FY2022 · CA

Stanford Cancer Institute

$4,223,653
Steven E Artandi · Stanford University · P30 · FY2024 · CA

Neuroblastoma Tumor Microenvironment: tumor growth and immune regulation

$4,216,302
Carol Thiele-Galetto · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Enhancing anti-tumor immunity in head and neck neoplasms

$4,097,112
Clint Allen · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

$4,075,119
Anish Thomas · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

CCR Collaborative Bioinformatics Resource

$4,057,258
Mariam Malik · Division Of Basic Sciences - Nci · ZIC · FY2025 · CA

T-Cell Receptor Gene Therapy for Human Cancers-Cures

$4,051,073
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA